The National Cancer Institute is considering granting an exclusive patent license to Senti Bio for developing and commercializing certain therapies that target CD33-expressing cancers. These therapies involve using specially engineered immune cells, like T cells and NK cells, to recognize and attack cancer cells marked by the CD33 protein, commonly found in acute myeloid leukemia. People interested in this license must submit their comments or applications by January 29, 2021. The patent rights involved have been assigned to the U.S. government, and the license could apply worldwide.
Simple Explanation
The National Cancer Institute is thinking about giving a company named Senti Bio special permission to use a new cancer treatment that helps a type of immune cell find and fight certain cancer cells. Some people are worried because the decision might not seem fair, it uses confusing words, and doesn't give people much time to say what they think.